pharmaphorum
OCTOBER 6, 2022
Not only does the appearance of a common symptom – such as a fever, for example – lead to potential misdiagnoses, but it can also lead to clinicians choosing ineffective therapies that treat symptoms, rather than the true cause of a disease. Tinker, tailor, soldier, therapy.
European Pharmaceutical Review
OCTOBER 19, 2023
Can you share an update on the clinical trial for your lead candidate? One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the side effects that are commonly experienced with chemotherapy. Barrett at the Center for Gamma Ray Imaging.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 22, 2023
Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5
Celeritas
NOVEMBER 21, 2022
They only partially impact the target areas and have damaging side effects in adjacent regions. Gold nanowires further positively impact key organ transplant functions – synapse formation and stem cell differentiation – all without using growth factors, which cause negative side effects. 16 August 2005).
Pharma Marketing Network
JUNE 11, 2020
So that was 2005. But you’d have to have one click to the side effects. John Mack (PG): But the industry evolved from there and they have the side effects on the same page. Who wants to deal with facts? RJ Lewis (EHS): Today, not many people apparently. It’s a blog. You were on Twitter very early.
Expert insights. Personalized for you.
98 
Let's personalize your content